TORONTO, June 14, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:
KHRNF), (Frankfurt: A2JMZC), a
cannabis company with core operations in Latin America, today announced the appointment
of Wendy Kaufman as CFO, effective
July 2, 2019. Ms. Kaufman, a
Chartered Professional Accountant, brings over 20 years of
international financial experience, having served most recently as
CFO at Pasinex Resources Limited. Ms. Kaufman has significant
experience with Latin American operations, gained during her tenure
as CFO at Primero Mining Corporation, and previously in her role as
Vice President, Finance and Treasury at Inmet Mining Corporation,
among other executive management positions.
Alvaro Torres, CEO of Khiron,
stated, "On behalf of our management team and Board of Directors, I
welcome Wendy to Khiron. We are confident that Wendy's
financial leadership and experience will be of great value to
Khiron and our stakeholders as we continue to grow our operations
and brands in Latin America and
internationally."
Ms. Kaufman will be replacing Mr. Darren
Collins who has concurrently resigned his position as CFO to
pursue other interests. Mr. Collins has agreed to remain with
the Company for an appropriate period in a transitional role.
Mr. Torres stated, "On behalf of the Board of Directors and the
entire Khiron team, I would like to thank Darren for his invaluable
contributions and leadership as the founding CFO of the
company. Darren has helped to build Khiron into the company
it is today. We wish him the very best in his future
endeavors."
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Latin America and is fully licensed in the
country for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based cannabis company to trade on any exchange
globally.
With a focused regional strategy and patient oriented approach,
the Company combines global scientific expertise, agricultural
advantages, branded product market entrance experience and
education to drive prescription and brand loyalty to address
priority medical conditions such as chronic pain, epilepsy,
depression and anxiety in the Latin American market of over 620
million people. Khiron is led by Co-founder and Chief Executive
Officer, Alvaro Torres, together
with an experienced executive team, and a knowledgeable Board of
Directors that includes former President of Mexico, Vicente
Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
To be added to the distribution list, please email
khiron@kcsa.com with "Khiron" in the subject line.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile at www.sedar.com.
The forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-changes-to-leadership-team-with-appointment-of-wendy-kaufman-as-cfo-300867653.html
SOURCE Khiron Life Sciences Corp.